Mark Taylor hired to build international expansion and develop institutional relationships
Obagi Medical Products, a pharmaceutical skincare company headquartered in Long Beach, California, has announced the appointment of Mark Taylor as senior vice president of corporate development and investor relations.
Taylor joins from Roth Capital Partners, a boutique investment bank, where he was responsible for institutional sales for the pharmaceutical and biotechnology sectors.
He first joined Roth in 2003 as a pharmaceuticals analyst, moving on to become vice president of global diagnostics at MP Biomedicals in 2008.
Prior to this, he served as vice president of business development at Watson Pharmaceuticals from 1997 to 1999. In 1999 he joined ICN Pharmaceuticals as an executive vice president for North America in charge of developing the company’s dermatology business.
Taylor holds a BSc in management from Tulane University.
Commenting on the appointment, Obagi’s CEO Albert Hummel says in a press release: ‘We are extremely pleased to welcome Mark to our team. He brings valuable experience, insights and a particular skill base that can readily assist us in our mission to build a much larger and more valuable company. In this new role, Mark will work with the team to build the base business internationally as well as to identify new sources of revenue from licensing, acquisition and strategic partnerships. Additionally, because of his unique experience with institutional investors, Mark will assist me and Preston Romm in investor relations.’
Candice de Monts-Petit
Candice de Monts-Petit joined IR Magazine as a senior editor in 2012. Prior to this, she worked in investor relations, first as an IRO for oil and gas firms in Paris and Moscow and subsequently as an IR consultant in London. She graduated in business...
